Table 2.
Top 10 most highly expressed genes in the “intermediate” phase (3-6 hours) of induction resulting from treatment with a 200-nM dose of CDDO-Im in HUVEC.
| Symbol | Name | 0.5 h | 1 h | 3 h | 6 h | 24 h |
|---|---|---|---|---|---|---|
| NOG | Noggin | 12.2 | 31.5 | 24.6 | 0.7 | 0.7 |
| F3 | Coagulation factor III (thromboplastin, tissue factor) | 2.9 | 5.7 | 9.2 | 5.6 | 1.3 |
| DACT1 | Dapper, antagonist of β-catenin, homolog 1 (Xenopus laevis) | 2.3 | 8.5 | 8.2 | 1.4 | 0.9 |
| HMOX1 | Heme oxygenase (decycling) 1 | 1.7 | 5.2 | 8.0 | 7.7 | 6.2 |
| ATOH8 | Atonal homolog 8 (Drosophila) | 1.9 | 7.9 | 7.2 | 1.4 | 1.4 |
| CLDN23 | Claudin 23 | 6.1 | 13.0 | 5.6 | 1.4 | 2.2 |
| HEY1 | Hairy/enhancer of split related to YRPW motif 1 | 43.6 | 55.7 | 5.4 | 0.9 | 1.2 |
| ALPK2 | Alpha-kinase 2 | 1.8 | 1.0 | 5.4 | 1.0 | 2.1 |
| FZD7 | Frizzled family receptor 7 | 6.8 | 20.8 | 5.3 | 4.1 | 0.9 |
| RASL1B | RAS-like, family 11, member B | 8.4 | 16.9 | 5.1 | 0.9 | 0.4 |
Abbreviations: CDDO-Im, 1[2-cyano-3,12-dioxooleana-1,9(11)-dien-28-oyl]imidazole; HUVEC, human umbilical vein endothelial cells.
Values at each time point represent fold change compared with control (dimethyl sulfoxide vehicle–treated HUVEC at time 0) after normalization to housekeeping genes.